The Best of the AACR Journals Collection: Author Profiles
Title & Affiliation:
Professor, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
Q: What is your primary area of study/research?
A: Gastrointestinal Oncology
Q: What influenced your decision to embark on a research career?
A: My tutors and their enthusiasm for research influenced me.
Q; What excites you most about your research area?
A: Checkpoint inhibitor in combination with anti-angiogenic agent (for example, PD-1 antibody plus apatinib) achieved encouraging efficacy for unresectable hepatocellular carcinoma (HCC).
Q: What do you do for fun outside of work? What are your passions and hobbies?
A: Reading international news, listening to light music, and traveling.
Read The Best of the AACR Journals
See the rest of the authors featured in The Best of the AACR Journals Collection for 2022